Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,177

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Open access
Gettinger, Scott N., Horn, Leora, Gandhi, Leena, Spigel, David R., Antonia, Scott J., Rizvi, Naiyer A., Powderly, John D., Heist, Rebecca S., Carvajal, Richard D., Jackman, David M., Sequist, Lecia V., Smith, David C., Leming, Philip, Carbone, David P., Pinder-Schenck, Mary C., Topalian, Suzanne L., Hodi, F. Stephen, Sosman, Jeffrey A., Sznol, Mario, McDermott, David F., Pardoll, Drew M., Sankar, Vindira, Ahlers, Christoph M., Salvati, Mark, Wigginton, Jon M., Hellmann, Matthew D., Kollia, Georgia D., Gupta, Ashok K., Brahmer, Julie R.·2015·Journal of Clinical Oncology
DOI 10.1200/jco.2014.58.3708
Open this paper in CoChat — free account

Abstract

Purpose: Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was active and generally well tolerated in patients with advanced solid tumors treated in a phase I trial with expansion cohorts. We report overall survival (OS), response durability, and long-term safety in patients with non–small-cell lung cancer (NSCLC) receiving nivolumab in this trial. Patients and Methods: Patients (N = 129) with heavily pretreated advanced NSCLC received nivolumab 1, 3, or 10 mg/kg intravenously once every 2 weeks in 8-week cycles for up to 96 weeks. Tumor burden was assessed by RECIST (version 1.0) after each cycle. Results: Median OS across doses was 9.9 months; 1-, 2-, and 3-year OS rates were 42%, 24%, and 18%, respectively, across doses and 56%, 42%, and 27%, respectively, at the 3-mg/kg dose (n = 37) chosen for further clinical development. Among 22 patients (17%) with objective responses, estimated median response duration was 17.0 months. An additional six patients (5%) had unconventional immune-pattern responses. Response rates were similar in squamous and nonsquamous NSCLC. Eighteen responding patients discontinued nivolumab for reasons other than progressive disease; nine (50%) of those had responses lasting > 9 months after their last dose. Grade 3 to 4 treatment-related adverse events occurred in 14% of patients. Three treatment-related deaths (2% of patients) occurred, each associated with pneumonitis. Conclusion: Nivolumab monotherapy produced durable responses and encouraging survival rates in patients with heavily pretreated NSCLC. Randomized clinical trials with nivolumab in advanced NSCLC are ongoing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.58.3708

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 28

  1. 10.1016/j.ccm.2011.08.017 · DOI
  2. 10.1378/chest.12-2361 · DOI
  3. 10.1200/JCO.2012.46.1764 · DOI · Paper page
  4. 10.1056/NEJMoa1006448 · DOI · Paper page
  5. 10.1038/70932 · DOI · Paper page
  6. 10.1084/jem.192.7.1027 · DOI · Paper page
  7. 10.1073/pnas.192461099 · DOI · Paper page
  8. 10.1016/j.coi.2011.12.009 · DOI · Paper page
  9. 10.1158/1078-0432.CCR-09-1624 · DOI · Paper page
  10. 10.1097/00000421-198212000-00014 · DOI · Paper page
  11. 10.1200/JCO.2005.08.043 · DOI · Paper page
  12. 10.1158/1078-0432.CCR-11-2109 · DOI · Paper page
  13. Gettinger SN, 2014, Intl J Radiat Oncol Biol Phys, 90, 5s
  14. 10.1093/annonc/mdu349.8 · DOI
  15. Topalian SL, 2013, J Clin Oncol, 31, 173s, 10.1200/jco.2013.31.15_suppl.3002 · DOI
  16. 10.1200/JCO.2000.18.10.2095 · DOI · Paper page
  17. 10.1200/JCO.2004.08.163 · DOI · Paper page
  18. 10.1097/JTO.0b013e3181bbf223 · DOI
  19. 10.1200/jco.2014.32.15_suppl.6582 · DOI
  20. 10.1016/j.cllc.2011.06.008 · DOI
  21. 10.1016/j.ijrobp.2014.09.038 · DOI
  22. 10.1093/annonc/mdu438.51 · DOI
  23. Rizvi N, 2014, Intl J Rad Oncol Biol Biophys, 90, 5s
  24. Horn L, Presented at the International Association for the Study of Lung Cancer 14th World Conference on Lung Cancer
  25. 10.1200/jco.2014.32.15_suppl.8024 · DOI
  26. 10.1200/jco.2014.32.15_suppl.8021 · DOI
  27. 10.1200/jco.2014.32.15_suppl.8020 · DOI
  28. 10.1200/jco.2014.32.15_suppl.8007 · DOI

Cited by

See all 1,177

Metadata

Authors
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., Sequist, L. V., Smith, D. C., Leming, P., Carbone, D. P., Pinder-Schenck, M. C., Topalian, S. L., Hodi, F. S., Sosman, J. A., Sznol, M., McDermott, D. F., Pardoll, D. M., Sankar, V., Ahlers, C. M., Salvati, M., Wigginton, J. M., Hellmann, M. D., Kollia, G. D., Gupta, A. K., & Brahmer, J. R.
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2015-06-20
Volume
33
Issue
18
Pages
2004-2012
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2014.58.3708
OpenAlex
W2143488876
Cited by
1,177
References
10
FWCI
77.75
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.2014.58.3708
The paper
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., Sequist, L. V., Smith, D. C., Leming, P., Carbone, D. P., Pinder-Schenck, M. C., Topalian, S. L., Hodi, F. S., Sosman, J. A., Sznol, M., . . . Brahmer, J. R. (2015). Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.58.3708

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.